HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Editorial: which biologic is next for ulcerative colitis patients who fail a subcutaneous anti-TNF?

AuthorsAhmad Albshesh, Shomron Ben-Horin
JournalAlimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 51 Issue 11 Pg. 1198-1199 (06 2020) ISSN: 1365-2036 [Electronic] England
PMID32424929 (Publication Type: Editorial, Comment)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Tumor Necrosis Factor-alpha
  • vedolizumab
  • Infliximab
Topics
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Cohort Studies
  • Colitis, Ulcerative
  • Humans
  • Infliximab
  • Tumor Necrosis Factor-alpha

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: